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012.10.0Abstract Background: Using drug eluting stents with a biodegradable polymer ensures that both
the drug and coating are absorbed from the stent surface after completing their functions, which
may reduce the need for prolonged antiplatelet therapy and decrease the risk of late stent thrombo-
sis.
Objectives: Our study sought to compare the safety and efﬁcacy of a biolimus-eluting stent (with
biodegradable polymer) with a well-established sirolimus- or paclitaxel-eluting stent (with durable
polymers).
Methods: We undertook a prospective, randomized, comparative study that included 145 patients
with chronic stable coronary artery diseases or acute coronary syndromes. The patients were ran-
domized for treatment with either biolimus-eluting (n= 62) or sirolimus/paclitaxel-eluting (n= 83)
stents. The study endpoint was a composite of major adverse cardiac events (MACE) within 2 years.
Angiographic follow-up was scheduled at the end of the study or earlier if clinically indicated.
Results: At the two-year follow-up, a biodegradable polymer biolimus-eluting stent showed com-
parable safety and efﬁcacy to permanent polymer DES(5[8.1%] patients in the biolimus group
vs.8[9.6%] in the sirolimus/paclitaxel group, p= 0.7). The incidence of mortality, myocardial
infarction, cerebrovascular accident and target lesion revascularization was similar for both stent
types. Furthermore, the incidence of stent thrombosis was statistically non-signiﬁcant between both
the groups.
Conclusion: The use of a biodegradable polymer-based DES (biolimus-eluting) demonstrated sat-
isfactory efﬁcacy and safety proﬁles with low MACE and stent thrombosis rates up to 2 years com-
pared with other non-biodegradable polymer-based DES.
ª 2012 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.; fax: +20 974 44327303.
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011. Introduction
Drug-eluting stents (DES) that facilitate controlled local re-
lease of antiproliferative drugs from a durable polymer delivery
system have been shown to signiﬁcantly reduce angiographic
restenosis compared with bare-metal stents (BMS).1,2 The asso-
ciated reduction in subsequent repeat revascularization confers
no signiﬁcant differences in mortality or myocardial infarctiong by Elsevier B.V. All rights reserved.
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continues to have some limitations, such as the increased risk
of late stent thrombosis (LST) caused by delayed arterial heal-
ing with incomplete reendothelialization and/or a chronic
inﬂammatory response.4,5 Although reendothelialization is
multi-factorial in cause, durable polymer surface coatings can
have a role.6 Therefore, recent guidelines recommend that dual
antiplatelet therapy (thienopyridine and aspirin) can be pre-
scribed (if tolerated) for at least 1 year after the DES implanta-
tion to protect against possible stent thrombosis (ST).7 To
maintain the antiproliferative effect of conventional DES and
allow the complete reendothelialization (hopefully minimizing
the LST risk and the required duration of dual antiplatelet ther-
apy), several trials are testing DES with biodegradable poly-
mers. These biodegradable polymers, which are currently
loaded on the metallic stent to deliver drugs, completely erode
by the time the drug has been released; however, the stent itself
is still maintained in the vessel wall.8 To date, data concerning
the safety and efﬁcacy of these stents are limited.
2. Aim of the work
In the current study, we aimed to compare the safety and efﬁ-
cacy of the biolimus-eluting stent (with biodegradable poly-
mer) with an established and widely used sirolimus or
paclitaxel-eluting stent (with durable polymers) in routine clin-
ical practice.
3. Methods
3.1. Study population
This prospective study was conducted from February 2007 to
December 2009. Institutional approval was obtained from the
University of Science and Technology Hospital (Yemen), and
the patients provided informed written consent.
3.1.1. Inclusion criteria
The patients with chronic stable coronary artery disease or
acute coronary syndromes, including non-ST-elevation and
ST-elevation myocardial infarction, were eligible for the study
if they had at least one lesion with a diameter stenosis P70%
that was suitable for coronary stent implantation in one or
more of the native vessels. We set no limit on the number of
treated lesions, vessels, or lesion length.
3.1.2. Exclusion criteria
Patients with a target lesion located in the left main stem, car-
diogenic shock, malignancies, or other co-morbid conditions
with life expectancy <12 months were excluded.
3.2. Study protocol
After undergoing diagnostic coronary angiography, the pa-
tients were randomly assigned to either Group I (biodegradable
polymer DES, biolimus-eluting stent) or Group II (permanent
polymer DES, either sirolimus-eluting or paclitaxel-eluting).
Our study included 156 patients, we performed balloon
angioplasty and stent implantation, according to standard
techniques; direct stenting was allowed. Full lesion coverage
was attempted by implanting one or several stents. Mixeddrug-eluting stents were not allowed in any patient. Before the
procedure, the patients were given 300 mg of acetylsalicylic
acid, a loading dose of 300–600 mg of clopidogrel, and
70–100 IU/kg of unfractionated heparin. The use of glycopro-
tein IIb/IIIa antagonists was left to the operator’s discretion.
After the intervention, the patients were prescribed 100 mg/
day of aspirin indeﬁnitely, 75 mg/day of clopidogrel for
6 months for Group I and12 months for Group II, while other
cardiac medications were prescribed based on the patient’s
condition (e.g., beta/blockers, ACE/inhibitors, and statins).
3.3. Data collection and study endpoints
The relevant data, such as the baseline criteria, procedural de-
tails and follow-up outcomes, were collected using forms. The
clinical status and adverse events were assessed at 1, 3, 6, 12, 18
and 24 months after the stent implantation. The study end-
point was a composite of major adverse cardiac events
(MACE) including death, myocardial infarction, cerebrovas-
cular accident, target lesion revascularization (TLR) or stent
thrombosis at 24 months post-index intervention. The MI
diagnosis was based on recurrent chest pain that lasted
>30 min and either new ECG changes that were consistent
with a second MI, or a next CK/MB level that was elevated
at least 50% above the previous level (taken a minimum of
8–12 h after the PCI) for the patients presenting with NSTE/
ACS and elevated CK/MB levels, or acute myocardial infarc-
tion with ST elevation prior to the PCI. While the increase in
CK/MB that wasP3 times the normal upper limit (ULN) and
at least 50% over the most recent pre-PCI levels, or developing
new ECG changes that were consistent with MI and CK/MB
elevations that were greater than the ULN (based on two mea-
surements) for the patients who presented with stable angina
pectoris or non ST-segment elevation acute coronary syn-
drome (NSTE/ACS) and normal CK/MB levels prior to the
PCI were diagnostic of second MI. Target lesion revasculariza-
tion was deﬁned as any repeated intervention that occurred
inside the implanted stent during the index procedure or
within 5 mm proximal or distal to the implanted stent. Stent
thrombosis was classiﬁed as deﬁnite, probable, and possible
according to the deﬁnitions proposed by the Academic
Research Consortium9; thrombosis was also stratiﬁed as acute
(<24 h), subacute (24 h–30 days), late (30 days–1 year) and
very late (>1 year). The angiographic follow-up was scheduled
at the end of the study or earlier if clinically indicated.
4. Statistical analysis
Comparisons between continuous variable data, which were
expressed as mean ± SD, were performed with Student’s
t-test, while the chi-squared or the Fisher’s exact tests were
used for the categorical data, which were expressed as percent-
ages. A p value < 0.05 was considered statistically signiﬁcant.5. Results
5.1. Baseline demographic variables for study patients
A total of 156 patients were enrolled in our study; 93% of
these patients completed the study. Sixty-two patients were
assigned to receive biodegradable polymer biolimus-eluting
Table 2 Comparison of angiographic and procedure charac-
teristics among study patients.
Group I
(62 pts)
Group II
(83pts)
p value
LAD location no. (%) 38 (61.3%) 53 (63.9%) 1
Type B/C lesion no. (%) 37 (59.7%) 55 (66.3%) 0.5
Single vessel disease no. (%) 52 (83.9%) 60 (72.3%) 0.3
Two vessel disease no. (%) 8 (12.9%) 19 (22.9%) 0.5
Three vessel disease no. (%) 2 (3.2%) 4 (4.8%) 1
No. of vessel/patient 1.2 ± 0.4 1.4 ± 0.6 0.06
No. of stent/patient 1.7 ± 0.8 1.8 ± 0.7 0.4
Direct stenting no. (%) 30 (48.4%) 42 (50.6%) 0.7
Table 1 Baseline demographic variables for study patients.
Group I
(62 pts)
Group II
(83 pts)
p value
Age (mean) 56.7 ± 11.2 54.2 ± 10.3 0.2
Sex (male %) 54 (87.1%) 71 (85.5%) 0.8
BMI (mean) 21.2 ± 2.8 20.7 ± 3 0.07
Smoking (%) 22 (35.5%) 29 (34.9%) 0.9
HTN (%) 36 (58.1%) 45 (54.2%) 0.6
DM (%) 22 (35.5%) 39 (47%) 0.6
Dyslipidemia (%) 16 (25.8%) 30 (36.1%) 0.2
Renal imp (%) 6 (9.7%) 4 (4.8%) 0.7
Previous revascularization (%) 6 (9.7%) 4 (4.8%) 0.7
Previous MI (%) 6 (9.7%) 10 (12%) 0.3
Presentation
 Stable angina 20 (32.2%) 24 (28.9%) 0.2
 Unstable angina 14 (22.6%) 20 (24.1%) 0.3
 NSTEMI 14 (22.6%) 16 (19.3%) 1
 STEMI 14 (22.6%) 23 (27.7%) 0.4
Medications
 Glycoprotein IIb/IIIA 47 (75.8%) 61 (73.5%) 0.3
 Aspirin 62 (100%) 83 (100%) 1
 BB 50 (80.6%) 74 (89.2%) 0.07
 ACE Is 28 (45.2%) 44 (53%) 0.4
 Plavix 62 (100%) 83 (100%) 1
 CCB 0 (0%) 0 (0%) 1
 Statin 62 (100%) 83 (100%) 1
Table 3 Long term outcomes.
(%) Group I
(62pts) (%)
Group II
(83pts) (%)
p value
Death no. 1 (1.6) 1 (1.2) 0.8
CVA no. 2 (3.2) 2 (2.4) 0.8
TLR no. 4 (6.5) 6 (7.2) 0.6
MI no. 2 (3.2) 2 (2.4) 0.7
Stent thrombosis no. 1 (1.6) 1 (1.2) 0.8
MACE no. 5 (8.1) 8 (9.6 0.7
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paclitaxel-eluting stents. Baseline demographic characteristics
were evenly distributed, and no signiﬁcant differences were de-
tected between the two study groups (Table 1).
5.2. Angiographic and procedural characteristics
The baseline angiographic and procedural characteristics are
listed in (Table 2) with no signiﬁcant difference between the
groups. In Group I, 61.3% of the included patients in the study
had LAD as a target vessel vs. 63.9% of the patients in Group
II (p> 0.05). In Group I, 1.2 + 0.4 vessels were treated per pa-
tient, and 1.7 + 0.8 stents were used per patient; in Group II,
1.4 + 0.6 vessels per patient were treated, and 1.8 + 0.7 stents
were used, (p> 0.05). Thirty Group I patients and 42 Group II
patients were treated with direct stenting (p> 0.05). Most of
the patients included in the study had single vessel disease(83.9% vs. 72.3%, p> 0.05), and more than half of the treated
lesions were type B–C in both groups.
5.3. Long term outcomes
Throughout the two-year follow-up, the incidence of MACE
was 8.1% for the Group I and 9.6% for Group II
(p> 0.05). In Group I, one case of late stent thrombosis was
recorded 11 months following the index procedure; in Group
II, another case of very late stent thrombosis was recorded
after 16 months (1.6% vs. 1.2%, respectively, p= 0.8). One
patient (1.6%) in Group I died from a new MI and another pa-
tient died (1.2%) in Group II after a cerebrovascular accident
(p= 0.8) (Table 3).
As shown in Fig. 1, there were no signiﬁcant differences
between the patients in Group I or Group II regarding the
composite MACE rate and the individual rates of recurrent
MI, TLR, cerebrovascular accidents, stent thrombosis and
mortality.
6. Discussion
This present prospective randomized study indicated that
although the enrolled patients (Group I) received only
6 months of dual antiplatelet therapy, the safety and efﬁcacy
of the biodegradable DES were satisfactory in real-world prac-
tice compared with the non-biodegradable DES and provided
low MACE rates.
The efﬁcacy of drug eluting stents (DES) for preventing
restenosis and reducing the risk of revascularization has been
proven in numerous clinical trials.10 However, these stents
simultaneously inhibit the physiological healing process of
the vessel wall, prolong the inﬂammatory reaction and ad-
versely affect the restoration of correctly functioning endothe-
lium.11 Several recent studies have suggested that delayed local
vessel healing increases the risk of potentially fatal late stent
thrombosis and may be attributed to the durable polymer
coatings of DES.12,13 After the drug elution, polymer stays
on the stent surface and may continue to induce a local inﬂam-
matory reaction, impair healing, and eventually contribute to
late thrombosis.14,15 Prolonged dual antiplatelet therapy
(1 year minimum) after DES implantation has been recom-
mended to address the increased risk of late stent thrombosis;
however, long-term dual antiplatelet therapy is associated with
increased hemorrhagic events, ﬁnancial burden, variable pa-
tient compliance, and other side effects.16 Theoretically, this
scenario could be potentially avoided by using a biodegradable
polymer, which would be absorbed from the stent surface
shortly after the drug has been eluted. Biodegradation ensures
that both the drug and coating are absorbed from the stent
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Figure 1 Comparison of the study endpoints (p> 0.05). ST; stent thrombosis, CVA; cerebrovascular accident, MI; myocardial
infarction, TLR; target lesion revascularization, MACE; major adverse cardiac events. p> 0.05 was non-signiﬁcant.
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tal stent covered by neointima and endothelium without fur-
ther continuous irritation of the arterial wall. This process
may reduce the need for prolonged antiplatelet therapy and de-
crease the risk of late stent thrombosis.17
In our study, a biodegradable polymer biolimus-eluting stent
showed comparable long term safety and efﬁcacy to permanent
polymerDES (sirolimus–paclitaxel). At the two-year follow-up,
there was no signiﬁcant difference between the biodegradable
polymer biolimus eluting stent and permanent polymer DES
(sirolimus/paclitaxel) in the individual and cumulative MACE
rates. Our study enrolled 156 real world patients who were
‘‘all comers.’’ Eleven patients were lost to follow-up. The
patients were randomized for treatment with either biolimus-
eluting (n= 62) or sirolimus/paclitaxel-eluting (n= 83) stents.
The patients were analyzed for the composite of MACE at the
24-month follow-up period (5[8.1%] patients in the biolimus
group vs. 8[9.6%] in the sirolimus/paclitaxel group, p= 0.7).
The incidence of mortality (1[1.6%] vs. 1[1.2%], p= 0.8),
myocardial infarction (2[3.2%] vs. 2[2.4%], p= 0.7), cerebro-
vascular accident (2[3.2] vs. 2[2.4], p= 0.8) and target lesion
revascularization (4[6.5%] vs. 6[7.2%], p= 0.6) was similar
for both stent types. Furthermore, the incidence of stent
thrombosis was statistically non-signiﬁcant between the groups
(1[1.6%] vs. 1[1.2%], p= 0.8).
Several pilot studies have documented the feasibility, efﬁcacy
and safety ofDESwith biodegradable polymer. TheFUTURE I
trial enrolled 42 patients with de novo coronary lesions to ever-
olimus-eluting stents coated with a bioabsorbable polymer (27
patients) and compared them with a group using bare metal
stents (15 patients). The major adverse cardiac event rates were
low at 30 days and 6 months, without any early or late stent
thrombosis in either group (P = NS). Between 6 and
12 months, there were no additional reports of major adverse
cardiac events. The 6-month angiographic in-stent restenosis
rate was 0% vs. 9.1% (1 patient) (P = NS), with an associated
late loss of 0.11 mm versus 0.85 mm (p< 0.001). The
in-segment restenosis rate was 4% (1 patient) and 9.1%
(1 patient) (P = NS) for EES and BMS, respectively. There
was no late stent malapposition in either group. The safety
and efﬁcacy of the EES appeared to be sustained at 12 months.18
In another trial, a sirolimus-eluting stent coated with a bio-
absorbable PLA polymer (EXCEL stent) showed promise inpreventing neointimal proliferation, restenosis, and associated
clinical events. The acute procedural and in-hospital outcome
was uneventful. Furthermore, the safety and efﬁcacy of the
EXCEL stent appeared to be sustained at 6 months.19While
In ISAR –test 3 trial, both biodegradable-polymer and
polymer-free stents have a 1-year safety proﬁle similar to that
of the polymer-permanent stent. Whereas the PF stent showed
inferior efﬁcacy, the biodegradable-polymer stent is at
least as effective as the PP stent in terms of antirestenotic
efﬁcacy.20
Recently, a positive experience was obtained in a multicen-
ter registry of real-world de novo lesions that were treated with
a novel Luc-Chopin stent eluting paclitaxel from a bioabsorb-
able polymer. The safety proﬁle appeared excellent, as there
were no incidents of late thrombosis between 30 and 365 days
of clinical follow-up. The angiographically documented reste-
nosis was comparable to previous experiences with paclitaxel,
and the ischemia-driven revascularization rate was low.5
In ISAR 4, we found that a biodegradable polymer rapa-
mycin-eluting stent was not inferior to a permanent polymer
DES in a large-scale study powered for a composite clinical
safety and efﬁcacy endpoint. Furthermore, after 1 year, there
was no difference between the biodegradable polymer DES
and permanent polymer DES in individual efﬁcacy (TLR) or
safety (cardiac death/MI or stent thrombosis) endpoint
components.21
Two major trials have enrolled ‘‘all-comers’’ real-world pa-
tients, CREATE and LEADERS. The Multi-Center Registry
Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent
(CREATE) studied 2,077 ‘‘real-world’’ patients who were trea-
ted with Excel biodegradable polymer-coated sirolimus-eluting
stents. The results from this multicenter registry indicated that
although 80.5% of the discharged patients received 66 months
of dual antiplatelet treatment, the safety proﬁle of this novel
DES when used in real-world practice was satisfactory with
low rates of MACE, overall stent thrombosis, and late stent
thrombosis. At an 18-month follow-up, the major adverse car-
diac event rate was 3.1%, and the overall incidence of stent
thrombosis was 0.87%. The angiographic follow-up, per-
formed in 974 (31.6%) lesions from 653 patients (31.7%), re-
vealed a mean in-stent late lumen loss of 0.21 ± 0.39 mm.
The binary restenosis rates were 3.8% in-stent and 6.7% in-
segment.22 A sustained three-year clinical safety and efﬁcacy
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been demonstrated, as the clinical follow-up was completed
in 2025 (97.5%) patients at a three-year follow-up. The cumu-
lative MACE rate was 4.5% and the rate of stent thrombosis
was 1.53% at 3 years. At six months to 3 years, prolonged
clopidogrel therapy (>6 months) was not beneﬁcial in reduc-
ing the cumulative hazards of MACE (3.4% vs. 3.1%, log rank
p= 0.725) or stent thrombosis (1.5% vs. 0.6%, log rank
p= 0.053).23
In another large-scale, randomized, multi-center trial, a
biolimus-eluting stent with biodegradable polymer was shown
to be non-inferior to a sirolimus-eluting stent with durable
polymer in the composite endpoints of cardiac death, myocar-
dial infarction, or clinically-indicated TVR at 9 months. More-
over, the biolimus-eluting stent resulted in non-inferior
outcomes of the principal angiographic in-stent percentage
diameter stenosis. The LEADERS trial enrolled 1707 patients
aged 18 years or older with chronic stable coronary artery
disease or acute coronary syndromes; the patients were
centrally randomized to treatment with either biolimus-eluting
(n= 857) or sirolimus-eluting (n= 850) stents. All of the ran-
domized patients were analyzed for the primary endpoint at
9 months (79[9%] patients in the biolimus group vs. 89[11%]
in the sirolimus group, p for non-inferiority = 0.003, p for
superiority = 0.39). The frequency of cardiac death (14[1.6%]
vs. 21[2.5%], p for superiority = 0.22), myocardial infarc-
tion(49 [5.7%] vs. 39[4.6%], p= 0.30), and clinically-indicated
target vessel revascularization (38[4.4%]vs.47 [5.5%], p= 0.29)
was similar for both stent types. In the biolimus-eluting group,
168(79%) patients were available for the angiographic follow-
up; 167(78%) patients in the sirolimus-eluting group were
available. Biolimus-eluting stents were non-inferior to the sirol-
imus-eluting stents in in-stent percentage diameter stenosis
(20.9% vs. 23.3%, p for non-inferiority = 0.001, p for superior-
ity = 0.26).24 The ﬁndings of the three year follow-up were
available in 95% of the patients (812 treated with BES and
809 treated with SES) and supported the claim that the biode-
gradable polymer biolimus-eluting stent had equivalent safety
and efﬁcacy to the permanent polymer sirolimus-eluting stent
in an ‘‘all-comers’’ patient population. At 3 years, BES
remained non-inferior to SES for the primary endpoint of
major adverse cardiac events (composite of cardiac death,
myocardial infarction (MI) and clinically-indicated target
vessel revascularization (BES 15.7% vs. SES 19%, HR 0.82,
CI 0.65–1.03, p= 0.09).25
Recent past trials have studied different biodegradable-
polymer drug-eluting stents. The clinical performance of the
biodegradable polymer DES varies. This ﬁnding was docu-
mented by a meta-analysis of 22 studies (from January
2005 to October 2010) that was performed by Ahmed TA
and his colleagues; the study reviewed 22 studies, including
randomized and observational studies. In nine studies (2042
patients), biodegradable-polymer sirolimus eluting stents
(BioPol-SES) were implanted; in eight studies (1731 patients),
biodegradable polymer paclitaxel-eluting stents (BioPol-PES)
were implanted, and in seven studies (4491 patients), biode-
gradable-polymer biolimus-eluting stents (BioPol-BES) were
implanted. After 1 year, there was a higher risk of TLR with
the BioPol–PES (p= 0.01) and the BioPol–SES (p= 0.04)
compared to the BioPol–BES. After one year, stent thrombo-
sis was not statistically different between the studied groups
(overall p= 0.2).267. Study limitations
The present study was a single-center, relatively small sized
trial. Another limitation that must be considered is the use
of different stent platforms that were eluted with different
drugs. Future larger trials are recommended to compare iden-
tical stent platforms with similar drugs and different polymeric
coatings.
8. Conclusion
Using a biodegradable polymer-coated DES (Biolimus) to
treat patients in a real-world practice demonstrated satisfac-
tory efﬁcacy and safety proﬁles with low rates of MACE and
stent thrombosis up to 24 months compared with other non-
biodegradable polymer-coated DES (sirolimus or paclitaxel).
Consequently, the obligatory period of dual antiplatelet ther-
apy may be shortened, thereby enhancing overall clinical and
economic beneﬁts.
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